The nuclear oncoprotein Fra-1: a transcription factor knocking on therapeutic applications’ door

[1]  L. Tran,et al.  FRA1 contributes to MEK-ERK pathway-dependent PD-L1 upregulation by KRAS mutation in premalignant human bronchial epithelial cells. , 2020, American journal of translational research.

[2]  S. Cockcroft,et al.  CDP-Diacylglycerol Synthases (CDS): Gateway to Phosphatidylinositol and Cardiolipin Synthesis , 2020, Frontiers in Cell and Developmental Biology.

[3]  Hui Xie,et al.  Expression and function of FRA1 protein in tumors , 2019, Molecular Biology Reports.

[4]  K. Zibara,et al.  The AP-1 transcriptional complex: Local switch or remote command? , 2019, Biochimica et biophysica acta. Reviews on cancer.

[5]  Michael J. Emanuele,et al.  Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer , 2019, Science Signaling.

[6]  M. Maqbool,et al.  AP-1 Signaling by Fra-1 Directly Regulates HMGA1 Oncogene Transcription in Triple-Negative Breast Cancers , 2019, Molecular Cancer Research.

[7]  C. Klebanoff,et al.  T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance , 2019, Immunological reviews.

[8]  B. L. Caputto,et al.  Fra-1 and c-Fos N-Terminal Deletion Mutants Impair Breast Tumor Cell Proliferation by Blocking Lipid Synthesis Activation , 2019, Front. Oncol..

[9]  James S. Duncan,et al.  Intrinsic Resistance to MEK Inhibition through BET Protein–Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer , 2019, Molecular Cancer Research.

[10]  Chunyan Zhao,et al.  Endogenous interaction profiling identifies DDX5 as an oncogenic coactivator of transcription factor Fra-1 , 2019, Oncogene.

[11]  Emanuel J. V. Gonçalves,et al.  Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens , 2019, Nature.

[12]  R. Weinberg,et al.  Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells , 2019, Proceedings of the National Academy of Sciences.

[13]  R. Fodde,et al.  The inflammatory cytokine IL-6 induces FRA1 deacetylation promoting colorectal cancer stem-like properties , 2019, Oncogene.

[14]  G. Christofori,et al.  Gain Fat-Lose Metastasis: Converting Invasive Breast Cancer Cells into Adipocytes Inhibits Cancer Metastasis. , 2019, Cancer cell.

[15]  I. Wistuba,et al.  Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network. , 2018, Cancer research.

[16]  Jennifer Y. Zhang,et al.  UBE2N Promotes Melanoma Growth via MEK/FRA1/SOX10 Signaling. , 2018, Cancer research.

[17]  S. Bicciato,et al.  Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4 , 2018, Nature Medicine.

[18]  Johannes P. W. Grimm,et al.  BRAF inhibition causes resilience of melanoma cell lines by inducing the secretion of FGF1 , 2018, Oncogenesis.

[19]  S. Conrad,et al.  The role of AP-1 in self-sufficient proliferation and migration of cancer cells and its potential impact on an autocrine/paracrine loop , 2018, bioRxiv.

[20]  Wei Li,et al.  Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis , 2018, Genome research.

[21]  S. Reddy,et al.  FOSL1 Promotes Kras‐induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation , 2017, American journal of respiratory cell and molecular biology.

[22]  H. Matsubara,et al.  Fra-1 Regulates the Expression of HMGA1, Which is Associated with a Poor Prognosis in Human Esophageal Squamous Cell Carcinoma , 2017, Annals of Surgical Oncology.

[23]  E. Rozeman,et al.  Cancer Drug Addiction is Relayed by an ERK2-Dependent Phenotype Switch , 2017, Nature.

[24]  I. Iaccarino.  lncRNAs and MYC: An Intricate Relationship , 2017, International journal of molecular sciences.

[25]  M. Nykter,et al.  Oncogenic K-Ras upregulates ITGA6 expression via FOSL1 to induce anoikis resistance and synergizes with αV-Class integrins to promote EMT , 2017, Oncogene.

[26]  K. Gallo,et al.  MLK3 regulates FRA-1 and MMPs to drive invasion and transendothelial migration in triple-negative breast cancer cells , 2017, Oncogenesis.

[27]  C. Berking,et al.  The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation , 2017, Oncogene.

[28]  R. Weinberg,et al.  Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas. , 2017, Cancer research.

[29]  R. Treisman,et al.  ERK-Induced Activation of TCF Family of SRF Cofactors Initiates a Chromatin Modification Cascade Associated with Transcription , 2017, Molecular cell.

[30]  Ben S. Wittner,et al.  Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer , 2017, Oncotarget.

[31]  J. Cui,et al.  Dysregulation of Fra1 expression by Wnt/β-catenin signalling promotes glioma aggressiveness through epithelial–mesenchymal transition , 2017, Bioscience reports.

[32]  P. Khatri,et al.  An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer , 2017, Nature Communications.

[33]  Zhaoming Wang,et al.  A functional SNP rs1892901 in FOSL1 is associated with gastric cancer in Chinese population , 2017, Scientific Reports.

[34]  Xiaobo Wang,et al.  PKCθ-induced phosphorylations control the ability of Fra-1 to stimulate gene expression and cancer cell migration. , 2017, Cancer letters.

[35]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2017, Cell.

[36]  J. Rossi,et al.  Aptamers as targeted therapeutics: current potential and challenges , 2016, Nature Reviews Drug Discovery.

[37]  N. Zhang,et al.  miR-497 suppresses epithelial–mesenchymal transition and metastasis in colorectal cancer cells by targeting fos-related antigen-1 , 2016, OncoTargets and therapy.

[38]  Kai-Fu Tang,et al.  The Fra-1–miR-134–SDS22 feedback loop amplifies ERK/JNK signaling and reduces chemosensitivity in ovarian cancer cells , 2016, Cell Death and Disease.

[39]  Limei Liu,et al.  SIRT1 promotes epithelial-mesenchymal transition and metastasis in colorectal cancer by regulating Fra-1 expression. , 2016, Cancer letters.

[40]  I. Ng,et al.  Cancer-Associated Fibroblasts Regulate Tumor-Initiating Cell Plasticity in Hepatocellular Carcinoma through c-Met/FRA1/HEY1 Signaling. , 2016, Cell reports.

[41]  Jennifer Y. Zhang,et al.  FRA1 promotes squamous cell carcinoma growth and metastasis through distinct AKT and c-Jun dependent mechanisms , 2016, Oncotarget.

[42]  A. Shiotani,et al.  Selective activator protein‐1 inhibitor T‐5224 prevents lymph node metastasis in an oral cancer model , 2016, Cancer science.

[43]  L. Zhu,et al.  Tead and AP1 Coordinate Transcription and Motility. , 2016, Cell reports.

[44]  L. Wessels,et al.  Fra-1 is a key driver of colon cancer metastasis and a Fra-1 classifier predicts disease-free survival , 2015, Oncotarget.

[45]  Z. Zeng,et al.  Fra-1 is upregulated in gastric cancer tissues and affects the PI3K/Akt and p53 signaling pathway in gastric cancer. , 2015, International journal of oncology.

[46]  Xiangyi Zheng,et al.  MicroRNA-195-5p, a new regulator of Fra-1, suppresses the migration and invasion of prostate cancer cells , 2015, Journal of Translational Medicine.

[47]  Antonio Rosato,et al.  Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth , 2015, Nature Cell Biology.

[48]  A. Chalk,et al.  BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells , 2015, Scientific Reports.

[49]  M. Xue,et al.  Fra-1 is downregulated in cervical cancer tissues and promotes cervical cancer cell apoptosis by p53 signaling pathway in vitro. , 2015, International journal of oncology.

[50]  Reuven Agami,et al.  Genome-wide profiling of p53-regulated enhancer RNAs uncovers a subset of enhancers controlled by a lncRNA , 2015, Nature Communications.

[51]  J. Massagué,et al.  Therapy-induced tumour secretomes promote resistance and tumour progression , 2015, Nature.

[52]  C. Qian,et al.  Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial–mesenchymal transition , 2015, Carcinogenesis.

[53]  K. Dahlman-Wright,et al.  AP-1-mediated chromatin looping regulates ZEB2 transcription: new insights into TNFα-induced epithelial–mesenchymal transition in triple-negative breast cancer , 2015, Oncotarget.

[54]  A. Dhillon,et al.  FRA-1 as a driver of tumour heterogeneity: a nexus between oncogenes and embryonic signalling pathways in cancer , 2014, Oncogene.

[55]  E. Wagner,et al.  Fra-1/AP-1 induces EMT in mammary epithelial cells by modulating Zeb1/2 and TGFβ expression , 2014, Cell Death and Differentiation.

[56]  I. Jariel-Encontre,et al.  Transcriptional complexity and roles of Fra-1/AP-1 at the uPA/Plau locus in aggressive breast cancer , 2014, Nucleic acids research.

[57]  L. Tranchevent,et al.  RNA helicases DDX5 and DDX17 dynamically orchestrate transcription, miRNA, and splicing programs in cell differentiation. , 2014, Cell reports.

[58]  J. Yang,et al.  MicroRNA-19a-3p inhibits breast cancer progression and metastasis by inducing macrophage polarization through downregulated expression of Fra-1 proto-oncogene , 2014, Oncogene.

[59]  K. Dahlman-Wright,et al.  Genome-wide profiling of AP-1-regulated transcription provides insights into the invasiveness of triple-negative breast cancer. , 2014, Cancer research.

[60]  I. Haviv,et al.  Widespread FRA1-Dependent Control of Mesenchymal Transdifferentiation Programs in Colorectal Cancer Cells , 2014, PloS one.

[61]  Qiang Zhang,et al.  Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. , 2014, Cancer cell.

[62]  Evan G. Williams,et al.  Regulation of steatohepatitis and PPARγ signaling by distinct AP-1 dimers. , 2014, Cell metabolism.

[63]  J. Pringle,et al.  Plasticity of melanoma and EMT-TF reprogramming , 2013, Oncotarget.

[64]  J. Lachuer,et al.  A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. , 2013, Cancer cell.

[65]  A. Luo,et al.  MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1 , 2013, Oncogene.

[66]  Elgene Lim,et al.  Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells. , 2013, Cancer cell.

[67]  U. Landegren,et al.  Specific interactions between Smad proteins and AP-1 components determine TGFβ-induced breast cancer cell invasion , 2013, Oncogene.

[68]  S. Dry,et al.  Epigenetic Activation of AP1 Promotes Squamous Cell Carcinoma Metastasis , 2013, Science Signaling.

[69]  Kevin Struhl,et al.  NF-Y coassociates with FOS at promoters, enhancers, repetitive elements, and inactive chromatin regions, and is stereo-positioned with growth-controlling transcription factors , 2013, Genome research.

[70]  David A. Orlando,et al.  Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.

[71]  Sridhar Ramaswamy,et al.  Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis , 2013, Proceedings of the National Academy of Sciences.

[72]  E. Wagner,et al.  FOSL1 Controls the Assembly of Endothelial Cells into Capillary Tubes by Direct Repression of αv and β3 Integrin Transcription , 2013, Molecular and Cellular Biology.

[73]  G. Natoli,et al.  Noncoding transcription at enhancers: general principles and functional models. , 2012, Annual review of genetics.

[74]  H. Varmus,et al.  Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins , 2012, Proceedings of the National Academy of Sciences.

[75]  T Kivioja,et al.  Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis , 2012, Cell Death and Differentiation.

[76]  T. Golub,et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.

[77]  Jing Huang,et al.  Distinct regulatory mechanisms and functions for p53-activated and p53-repressed DNA damage response genes in embryonic stem cells. , 2012, Molecular cell.

[78]  Jian Jin,et al.  Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer , 2012, Cell.

[79]  A. Dhillon,et al.  Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL , 2012, Oncogene.

[80]  Kai-Fu Tang,et al.  MicroRNA-34a inhibits migration and invasion of colon cancer cells via targeting to Fra-1. , 2012, Carcinogenesis.

[81]  Dongsheng Yu,et al.  Molecular Characterization of the MicroRNA-138-Fos-like Antigen 1 (FOSL1) Regulatory Module in Squamous Cell Carcinoma* , 2011, The Journal of Biological Chemistry.

[82]  Yang Yu,et al.  Loss of breast epithelial marker hCLCA2 promotes epithelial to mesenchymal transition and indicates higher risk of metastasis , 2011, Oncogene.

[83]  Ru-Fang Yeh,et al.  TRPS1 Targeting by miR-221/222 Promotes the Epithelial-to-Mesenchymal Transition in Breast Cancer , 2011, Science Signaling.

[84]  E. Wagner,et al.  Elevated Fra-1 expression causes severe lipodystrophy , 2011, Journal of Cell Science.

[85]  S. Hurtley.  Time for a Pause , 2011, Science Signaling.

[86]  H. Ni,et al.  Fra-1 protooncogene regulates IL-6 expression in macrophages and promotes the generation of M2d macrophages , 2010, Cell Research.

[87]  J. Blenis,et al.  ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. , 2010, Molecular cell.

[88]  C. Liu,et al.  The Role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression , 2009, Oncogene.

[89]  Salvatore Oliviero,et al.  Histone Crosstalk between H3S10ph and H4K16ac Generates a Histone Code that Mediates Transcription Elongation , 2009, Cell.

[90]  Sumit Kumar,et al.  hCLCA2 Is a p53-Inducible Inhibitor of Breast Cancer Cell Proliferation. , 2009, Cancer research.

[91]  H. Pass,et al.  HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway. , 2008, American journal of respiratory cell and molecular biology.

[92]  A. Pintzas,et al.  Fra‐1 regulates vimentin during Ha‐RAS‐induced epithelial mesenchymal transition in human colon carcinoma cells , 2007, International journal of cancer.

[93]  J. Grande,et al.  Involvement of RNA helicases p68 and p72 in colon cancer. , 2007, Cancer research.

[94]  P. Verde,et al.  Fra‐1 promotes growth and survival in RAS‐transformed thyroid cells by controlling cyclin A transcription , 2007, The EMBO journal.

[95]  Zhi-Ren Liu,et al.  P68 RNA Helicase Mediates PDGF-Induced Epithelial Mesenchymal Transition by Displacing Axin from β-Catenin , 2006, Cell.

[96]  Nicholas A. Frost,et al.  Activator protein-1 activity regulates epithelial tumor cell identity. , 2006, Cancer research.

[97]  K. Belguise,et al.  FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells , 2005, Oncogene.

[98]  R. Xiang,et al.  Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[99]  M. Martinelli,et al.  Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma. , 2003, Cancer research.

[100]  E. Sahai,et al.  ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. , 2003, Cancer cell.

[101]  P. Verde,et al.  Accumulation of Fra-1 in ras-Transformed Cells Depends on Both Transcriptional Autoregulation and MEK-Dependent Posttranslational Stabilization , 2003, Molecular and Cellular Biology.

[102]  M. Bittner,et al.  Fluorescent cDNA microarray hybridization reveals complexity and heterogeneity of cellular genotoxic stress responses , 1999, Oncogene.

[103]  P. Verde,et al.  A regulatory element that mediates co‐operation between a PEA3‐AP‐1 element and an AP‐1 site is required for phorbol ester induction of urokinase enhancer activity in HepG2 hepatoma cells. , 1992, The EMBO journal.

[104]  R. Beatty.  Splitting of the optic nerve by a carotid-ophthalmic artery aneurysm. Case report. , 1986, Journal of neurosurgery.

[105]  E. Imyanitov,et al.  EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer. , 2019, Biochimica et biophysica acta. Reviews on cancer.

[106]  N. Sharpless,et al.  Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma. , 2018, Cancer discovery.

[107]  Xia Fang,et al.  Fra-1 is upregulated in lung cancer tissues and inhibits the apoptosis of lung cancer cells by the P53 signaling pathway. , 2016, Oncology reports.

[108]  E. Wagner,et al.  AP-1: a double-edged sword in tumorigenesis , 2003, Nature Reviews Cancer.